Infliximab Treatment in Resistant Pyoderma Gangrenosum: A Case Report


Creative Commons License

Durmaz Y., Bilgici A., Cil E. E., Kuru O.

TURKIYE FIZIKSEL TIP VE REHABILITASYON DERGISI-TURKISH JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, cilt.58, sa.4, ss.332-334, 2012 (SCI-Expanded) identifier identifier

Özet

Pyoderma gangrenosum (PG) is an uncommon neutrophilic dermatosis consisting of nodules and pustules that ulcerate. Pyoderma gangrenosum is associated with autoimmune disorders such as inflammatory bowel disease, spondyloarthritis, and rheumatoid arthritis. In mild disease, therapy consists of local wound care and topical or intralesional corticosteroids. For more severe disease, systemic agents are necessary. Herein, we present the case of a patient with steroid resistant pyederma gangrenosum associated with ulcerative colitis and ankylosing spondylitis who responded well to infliximab, a tumor necrosis factor blocker. Biological agents (anti-TNF) may be alternative treatment options in patients with resistant PG. Turk J Fhys Med Rehab 2012;58:332-4.